EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Allogene Therapeutics's enterprise value is $63.73 Mil.
Allogene Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00 Mil. Therefore, Allogene Therapeutics's EV-to-Revenue for today is .
The historical rank and industry rank for Allogene Therapeutics's EV-to-Revenue or its related term are showing as below:
ALLO'
s EV-to-Revenue Range Over the Past 10 Years
Min: -1746.27 Med: 52.93 Max: 4660.81
Current: 2896.64
During the past 8 years, the highest EV-to-Revenue of Allogene Therapeutics was 4660.81. The lowest was -1746.27. And the median was 52.93.
ALLO's EV-to-Revenue is ranked worse than 97.59% of 996
companies
in the Biotechnology industry
Industry Median: 7.685
vs ALLO: 2896.64
Allogene Therapeutics EV-to-Revenue Historical Data
The historical data trend for Allogene Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Allogene Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Allogene Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allogene Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Allogene Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Allogene Therapeutics's EV-to-Revenue falls into.
Allogene Therapeutics's current Enterprise Value is $63.73 Mil.
Allogene Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allogene Therapeutics's share price for today is $1.18.
Allogene Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allogene Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Allogene Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALLO has been successfully added to your 